• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Verastem - Articles and news items

Verastem licenses Duvelisib from Infinity Pharmaceuticals for $28 million

Industry news / 3 November 2016 / Niamh Louise Marriott, Digital Content Producer

Verastem licensed exclusive worldwide rights to develop and commercialise Infinity’s oncology product candidate duvelisib…

Phase 1 study of Verastem’s FAK inhibitor, VS-6063, starts

Industry news / 6 January 2016 / Victoria White

The Phase 1 study, initiated by Washington University, will evaluate VS-6063 in combination with pembrolizumab and gemcitabine in patients with pancreatic cancer…

Verastem reduces its workforce by 50%

Industry news / 9 October 2015 / Victoria White

Verastem’s announcement comes just weeks after the company had to abandon enrolment in a Phase 2 study of its lead cancer drug VS-6063…

Verastem stops enrolment in trial of VS-6063 in mesothelioma

Industry news / 28 September 2015 / Victoria White

While VS-6063 had a generally well tolerated safety profile, there was not a sufficient level of efficacy to warrant continuation of the study…